OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye...…
1,670$
-1,76%
Echtzeit-Aktienkurs OKYO Pharma Ltd. (ADRs)
Bid:
Ask:
Nachrichten zur OKYO Pharma Ltd. (ADRs) Aktie
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd (NASDAQ:OKYO),…
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share,…
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases,...…
OKYO Pharma appoints Flavio Mantelli as chief medical officer
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye...…
OKYO Pharma’s neuropathic corneal pain study greenlit by FDA
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week confirmed it is set to launch a Phase 2b/3 clinical trial for neuropathic…
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye...…
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following…
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) said on Friday the US Food and Drug Administration has authorized a single-patient expanded access, or…
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO
OKYO Pharma Ltd (NASDAQ:OKYO) has appointed ophthalmology veteran Robert Dempsey as its new CEO. The NASDAQ-listed, clinical-stage biopharmaceutical company...…
OKYO Pharma management team to ring Nasdaq opening bell
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its executive chairman and founder, Gabriele Cerrone, along with members of the company’s management…
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated...…
OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) plans to run a 100-patient, multi-centre study of its eye-drop candidate Urcosimod in neuropathic corneal pain,…
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company’s Phase…
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its…
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its…
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod…
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical…
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company’s chief executive, Gary Jacob, is set…
OKYO moves toward FDA talks after eye drug trial
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101)…
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the…
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic…
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company’s recent developments, including the formal naming of…
OKYO Pharma reports long-term shelf stability of corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a…
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug…
OKYO Pharma secures USAN designation ‘urcosimod’ for lead asset
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod."…
OKYO Pharma says OK-101 gains USAN reflecting role in ocular disease modulation
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod."…
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe
OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it…
OKYO Pharma insiders acquire shares
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company’s shares at US$1.04…
OKYO Pharma nears full enrollment for neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for…
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end
OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for…
OKYO Pharma secures non-dilutive funding to advance clinical programs
OKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing...…
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference
OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference…
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company’s Phase 2 clinical trial…
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational…
OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational…
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at…
OKYO Pharma secures key US patent for dry eye disease therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101’s use…
OKYO Pharma chairman acquires more shares in the company
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman…
OKYO Pharma lands European patent protection for lead asset
OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs…
OKYO Pharma neuropathic corneal pain trial to get underway in the third quarter
OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in…
OKYO Pharma dry eye disease trial to get underway in the third quarter
OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in…
OKYO Pharma shares encouraging dry eye data
OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The…
OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it is rescheduling its Key Opinion Leader event on the results of its Phase 2 trial…
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms
OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various…
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the…
OKYO Pharma to release Phase 2 dry eye disease trial results on Friday
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…
OKYO Pharma to release Phase 2 dry eye disease trial results
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…